In the ICD cascade, CRT can release “eat-me” signals on tumor cell membranes, recruit immature DCs to phagocytose tumor cell fragments, promote DCs to mature, and present antigens to reach lymph nodes to activate effector T cells (CD3+ CD8+ T cells), further enhancing the antitumor immune response [49]. Here, CD8A is linked to neoplasm.